Tamoxifen; succesverhaal
juli 29, 2011 7 reacties
Als
C Davies (Clinical Trial Service Unit [CTSU], Oxford, UK), J Godwin (CTSU), R Gray (CTSU), M Clarke (CTSU), D Cutter (CTSU), S Darby (CTSU), P McGale (CTSU), H C Pan (CTSU), C Taylor (CTSU), Y C Wang (CTSU), M Dowsett (Breakthrough Breast Cancer Centre, Institute of Cancer Research, Royal Marsden Hospital, London, UK), J Ingle (Mayo Clinic, Rochester, MN, USA), R Peto (CTSU).
Attendees at EBCTCG Steering Committee meetings
K Albain, S Anderson, R Arriagada, W Barlow, J Bergh, J Bliss, *M Buyse, D Cameron, E Carrasco, *† M Clarke, C Correa, A Coates, *† R Collins, J Costantino, † D Cutter, J Cuzick, *† S Darby, N Davidson, *† C Davies, † K Davies, † A Delmestri, A Di Leo, M Dowsett, † P Elphinstone, † V Evans, *M Ewertz, R Gelber, † L Gettins, C Geyer, A Goldhirsch, † J Godwin, † R Gray, † C Gregory, D Hayes, C Hill, J Ingle, R Jakesz, † S James, M Kaufmann, † A Kerr, † E MacKinnon, † P McGale, † T McHugh, L Norton, Y Ohashi, S Paik, † H C Pan, E Perez, *† R Peto, *M Piccart (co-chair), L Pierce, G Pruneri, *K Pritchard (co-chair), V Raina, P Ravdin, J Robertson, E Rutgers, YF Shao, S Swain, † C Taylor, P Valagussa, G Viale, T Whelan, *E Winer, † Y Wang, *W Wood (LOL@red Willy?). *Executive Group. † Secretariat.
ACETBC, Tokyo, Japan O Abe, R Abe, K Enomoto, K Kikuchi, H Koyama, H Masuda, Y Nomura, Y Ohashi, K Sakai, K Sugimachi, M Toi, T Tominaga, J Uchino, M Yoshida. Addenbrooke’s Hospital, Cambridge, UK J L Haybittle. Anglo-Celtic Cooperative Oncology Group, UK C F Leonard. ARCOSEIN Group, France G Calais, P Geraud. ATLAS Trial Collaborative Study Group, Oxford, UK V Collett, C Davies, A Delmestri, J Sayer. Auckland Breast Cancer Study Group, New Zealand V J Harvey, I M Holdaway, R G Kay, B H Mason. Australian New Zealand Breast Cancer Trials Group, Sydney, Australia J F Forbes, N Wilcken. Austrian Breast Cancer Study Group, Vienna, Austria R Bartsch, P Dubsky, C Fesl, H Fohler, M Gnant, R Greil, R Jakesz, A Lang, G Luschin-Ebengreuth, C Marth, B Mlineritsch, H Samonigg, C F Singer, G G Steger, H Stöger. Beatson Oncology Centre, Glasgow, UK P Canney, H M A Yosef. Belgian Adjuvant Breast Cancer Project, Liège, Belgium C Focan. Berlin-Buch Akademie der Wissenschaften, Germany U Peek. Birmingham General Hospital, UK G D Oates, J Powell. Bordeaux Institut Bergonié, France M Durand, L Mauriac. Bordet Institute, Brussels, Belgium A Di Leo, S Dolci, D Larsimont, J M Nogaret, C Philippson, M J Piccart. Bradford Royal Infirmary, UK M B Masood, D Parker, J J Price. Breast Cancer International Research Group (BCIRG) M A Lindsay, J Mackey, M Martin. Breast Cancer Study Group of the Comprehensive Cancer Centre, Limburg, Netherlands P S G J Hupperets. British Association of Surgical Oncology BASO II Trialists, London, UK T Bates, R W Blamey, U Chetty, I O Ellis, E Mallon, D A L Morgan, J Patnick, S Pinder. British Columbia Cancer Agency, Vancouver, Canada I Olivotto, J Ragaz. Cancer and Leukemia Group B, Washington DC, USA D Berry, G Broadwater, C Cirrincione, H Muss, L Norton, R B Weiss. Cancer Care Ontario, Canada H T Abu-Zahra. Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow, Russia S M Portnoj. Cancer Research UK Clinical Trials Unit (CRCTU), NCRI, Birmingham, UK S Bowden, C Brookes, J Dunn, I Fernando, M Lee, C Poole, D Rea, D Spooner. Cardiff Trialists Group, UK P J Barrett-Lee, R E Mansel, I J Monypenny. Case Western Reserve University, Cleveland, OH, USA N H Gordon. Central Oncology Group, Milwaukee, WI, USA H L Davis. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary, University of London, UK J Cuzick. Centre Léon-Bérard, Lyon, France Y Lehingue, P Romestaing. Centre Paul Lamarque, Montpellier, France J B Dubois.
Centre Regional François Baclesse, Caen, France T Delozier, B Griffon, J Mace Lesec’h. Centre René Huguenin, Paris, St Cloud, France P Rambert.
Centro Oncologico, Trieste, Italy G Mustacchi. Charles University in Prague, First Faculty of Medicine, Department of Oncology of the First Faculty of Medicine and General Teaching Hospital, Czech Republic L Petruzelka, O Pribylova. Cheltenham General Hospital, UK J R Owen. Chemo N0 Trial Group, Germany N Harbeck, F Jänicke, C Meisner, M Schmitt, C Thomssen. Chicago University, IL, USA P Meier. Chinese Academy of Medical Sciences, Beijing, People’s Republic of China (in collaboration with the Oxford CTSU) Y Shan, Y F Shao, X Wang, D B Zhao (CTSU: Z M Chen, H C Pan). Christie Hospital and Holt Radium Institute, Manchester, UK A Howell, R Swindell. Clinical Trial Service Unit, Oxford, UK (ie, EBCTCG Secretariat) J A Burrett, M Clarke, R Collins, C Correa, D Cutter, S Darby, C Davies, K Davies, A Delmestri, P Elphinstone, V Evans, L Gettins, J Godwin, R Gray, C Gregory, D Hermans, C Hicks, S James, A Kerr, E MacKinnon, M Lay, P McGale, T McHugh, R Peto, J Sayer, C Taylor, Y Wang. Coimbra Instituto de Oncologia, Portugal J Albano, C F de Oliveira, H Gervásio, J Gordilho. Copenhagen Radium Centre, Denmark H Johansen, H T Mouridsen. Dana-Farber Cancer Institute, Boston, MA, USA R S Gelman, J R Harris, D Hayes, C Henderson, C L Shapiro, E Winer. Danish Breast Cancer Cooperative Group, Copenhagen, Denmark P Christiansen, B Ejlertsen, M Ewertz, M-B Jensen, S Møller, H T Mouridsen. Danish Cancer Registry, Copenhagen, Denmark B Carstensen, T Palshof. Düsseldorf University, Germany H J Trampisch. Dutch Working Party for Autologous Bone Marrow Transplant in Solid Tumours, Amsterdam & Groningen, Netherlands O Dalesio, E G E de Vries, S Rodenhuis, H van Tinteren. Eastern Cooperative Oncology Group, Boston, MA, USA R L Comis, N E Davidson, R Gray, N Robert, G Sledge, L J Solin, J A Sparano, D C Tormey, W Wood. Edinburgh Breast Unit, UK D Cameron, U Chetty, J M Dixon, P Forrest, W Jack, I Kunkler. Elim Hospital, Hamburg, Germany J Rossbach. Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, Netherlands J G M Klijn, A D Treurniet-Donker, W L J van Putten. European Institute of Oncology, Milan, Italy N Rotmensz, U Veronesi, G Viale. European Organization for Research and Treatment of Cancer, Brussels, Belgium H Bartelink, N Bijker, J Bogaerts, F Cardoso, T Cufer, J P Julien, E Rutgers, C J H van de Velde. Evanston Hospital, IL, USA M P Cunningham. Finnish Breast Cancer Group, Finland R Huovinen, H Joensuu. Fondazione Maugeri Pavia, Italy A Costa, C Tinterri. Fondazione Michelangelo, Milan, Italy G Bonadonna, L Gianni, P Valagussa. Fox Chase Cancer Center, Philadelphia, PA, USA L J Goldstein. French Adjuvant Study Group (GFEA), Guyancourt, France J Bonneterre, P Fargeot, P Fumoleau, P Kerbrat, E Luporsi, M Namer. German Adjuvant Breast Group (GABG), Frankfurt, Germany W Eiermann, J Hilfrich, W Jonat, M Kaufmann, R Kreienberg, M Schumacher. German Breast Cancer Study Group (BMFT), Freiburg, Germany G Bastert, H Rauschecker, R Sauer, W Sauerbrei, A Schauer, M Schumacher. German Breast Group (GBG), Neu-Isenburg, Germany J U Blohmer, S D Costa, H Eidtmann, B Gerber, C Jackisch, S Loibl, G von Minckwitz. Ghent University Hospital, Belgium A de Schryver, L Vakaet. GIVIO Interdisciplinary Group for Cancer Care Evaluation, Chieti, Italy M Belfiglio, A Nicolucci, F Pellegrini, M C Pirozzoli, M Sacco, M Valentini. Glasgow Victoria Infirmary, UK C S McArdle, D C Smith, S Stallard. Groote Schuur Hospital, Cape Town, South Africa D M Dent, C A Gudgeon, A Hacking, E Murray, E Panieri, ID Werner. Grupo Español de Investigación en Cáncer de Mama (GEICAM), Spain E Carrasco, M Martin, M A Segui. Gruppo Oncologico Clinico Cooperativo del Nord Est, Aviano, Italy E Galligioni. Gruppo Oncologico Dell’Italia Meridionale (GOIM), Rome, Italy M Lopez. Guadalajara Hospital de 20 Noviembre, Mexico A Erazo, J Y Medina. Gunma University, Japan J Horiguchi, H Takei. Guy’s Hospital, London, UK I S Fentiman, J L Hayward, R D Rubens, D Skilton. Heidelberg University I, Germany H Scheurlen. Heidelberg University II, Germany M Kaufmann, H C Sohn. Helios Klinikum Berlin-Buch, Germany M Untch. Hellenic Breast Surgeons Society, Greece U Dafni, C Markopoulos. Hellenic Cooperative Oncology Group, Athens, Greece U Dafni, G Fountzilas. Hellenic Oncology Research Group, Greece D Mavroudis. Helsinki Deaconess Medical Centre, Finland P Klefstrom. Helsinki University, Finland C Blomqvist, T Saarto. Hospital del Mar, Barcelona, Spain M Gallen. Innsbruck University, Austria R Margreiter. Institut Claudius Regaud, Toulouse, France B de Lafontan, J Mihura, H Roché. Institut Curie, Paris, France B Asselain, R J Salmon, J R Vilcoq. Institut Gustave-Roussy, Paris, France R Arriagada, C. Bourgier, C Hill, S Koscielny, A Laplanche, M G Lê, M Spielmann. Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU, NCRI), UK R A’Hern, J Bliss, P Ellis, L Kilburn, J R Yarnold. Integraal Kankercentrum, Amsterdam, Netherlands J Benraadt, M Kooi, A O van de Velde, J A van Dongen, J B Vermorken. International Breast Cancer Study Group (IBCSG), Bern, Switzerland M Castiglione, A Coates, M Colleoni, J Collins, J Forbes, R D Gelber, A Goldhirsch, J Lindtner, K N Price, M M Regan, C M Rudenstam, H J Senn, B Thuerlimann. International Collaborative Cancer Group, Charing Cross Hospital, London, UK J M Bliss, C E D Chilvers, R C Coombes, E Hall, M Marty. International Drug Development Institute, Louvain-la-Neuve, Belgium M Buyse. International TABLE Study Group, Berlin, Germany K Possinger, P Schmid, M Untch, D Wallwiener. ISD Cancer Clinical Trials Team (incorporating the former Scottish Cancer Therapy Network), Edinburgh, UK L Foster, W D George, H J Stewart, P Stroner. Israel NSABC, Tel Aviv, Israel R Borovik, H Hayat, M J Inbar, E Robinson. Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy P Bruzzi, L Del Mastro, P Pronzato, M R Sertoli, M Venturini. Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy T Camerini, G De Palo, M G Di Mauro, F Formelli, P Valagussa. Istituto Oncologico Romagnolo, Forli, Italy D Amadori. Italian Cooperative Chemo-Radio-Surgical Group, Bologna, Italy A Martoni, F Pannuti. Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy R Camisa, G Cocconi, A Colozza, R Passalacqua. Japan Clinical Oncology Group—Breast Cancer Study Group, Matsuyama, Japan K Aogi, S Takashima. Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan O Abe, T Ikeda, K Inokuchi, K Kikuchi, K Sawa. Kawasaki Medical School, Japan H Sonoo. Krakow Institute of Oncology, Poland S Korzeniowski, J Skolyszewski. Kumamoto University Group, Japan M Ogawa, J Yamashita. Leiden University Medical Center, Netherlands E Bastiaannet, C J H van de Velde, W van de Water, J G H van Nes. Leuven Akademisch Ziekenhuis, Gasthuisberg, Belgium R Christiaens, P Neven, R Paridaens, W Van den Bogaert. Ludwig-Maximilians University, Munich, Germany S Braun, W Janni. Marseille Laboratoire de Cancérologie Biologique APM, France P Martin, S Romain. Medical University Vienna — General Hospital – Department of Obstetrics and Gynaecology and Department of Medicine I, Vienna, Austria M Janauer, M Seifert, P Sevelda, C C Zielinski. Memorial Sloan-Kettering Cancer Center, New York, NY, USA T Hakes, C A Hudis, L Norton, R Wittes. Metaxas Memorial Cancer Hospital, Athens, Greece G Giokas, D Kondylis, B Lissaios. Mexican National Medical Center, Mexico City, Mexico R de la Huerta, M G Sainz. National Cancer Institute, Bethesda, MD, USA R Altemus, K Camphausen, K Cowan, D Danforth, A Lichter, M Lippman, J O’Shaughnessy, L J Pierce, S Steinberg, D Venzon, J A Zujewski. National Cancer Institute of Bari, Italy C D’Amico, M Lioce, A Paradiso. NCIC Clinical Trials Group, Kingston, Ontario, Canada J-A W Chapman, K Gelmon, P E Goss, M N Levine, R Meyer, W Parulekar, J L Pater, K I Pritchard, L E Shepherd, D Tu, T Whelan. National Kyushu Cancer Center, Japan Y Nomura, S Ohno. National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA, USA S Anderson, G Bass, A Brown (deceased), J Bryant (deceased), J Costantino, J Dignam, B Fisher, C Geyer, E P Mamounas, S Paik, C Redmond, S Swain, L Wickerham, N Wolmark. Nolvadex Adjuvant Trial Organisation, London, UK M Baum, I M Jackson (deceased), M K Palmer. North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN, USA E Perez, J N Ingle, V J Suman. North Sweden Breast Cancer Group, Umeå, Sweden N O Bengtsson, S Emdin, H Jonsson. North-West Oncology Group (GONO), Italy L Del Mastro, M Venturini. North-Western British Surgeons, Manchester, UK J P Lythgoe, R Swindell. Northwick Park Hospital, London, UK M Kissin. Norwegian Breast Cancer Group, Oslo, Norway B Erikstein, E Hannisdal, A B Jacobsen, J E Varhaug. Norwegian Radium Hospital, Oslo, Norway B Erikstein, S Gundersen, M Hauer-Jensen, H Høst, A B Jacobsen, R Nissen-Meyer. Nottingham City Hospital, UK R W Blamey, A K Mitchell, D A L Morgan, J F R Robertson. Oita Prefectural Hospital, Japan H Ueo. Oncofrance, Paris, France M Di Palma, G Mathé (deceased), J L Misset. Ontario Clinical Oncology Group, Hamilton, Canada M Levine, K I Pritchard, T Whelan. Osaka City University, Japan K Morimoto. Osaka National Hospital, Japan K Sawa, Y Takatsuka. Oxford Radcliffe Hospitals NHS Trust, Churchill Hospital, Oxford, UK E Crossley, A Harris, D Talbot, M Taylor. PACS Adjuvant Study Group, France A L Martin, H Roché. Parma Hospital, Italy G Cocconi, B di Blasio. Petrov Research Institute of Oncology, St Petersburg, Russia V Ivanov, R Paltuev, V Semiglazov. Piedmont Oncology Association, Winston-Salem, NC, USA J Brockschmidt, M R Cooper. Pretoria University, South Africa C I Falkson. Royal Marsden NHS Trust, London and Sutton, UK R A’Hern, S Ashley, M Dowsett, A Makris, T J Powles, I E Smith, J R Yarnold. St George’s Hospital, London, UK J C Gazet. St George Hospital, Sydney, Australia L Browne, P Graham. St Luke’s Hospital, Dublin, Ireland N Corcoran. Sardinia Oncology Hospital A Businico, Cagliari, Sardinia N Deshpande, L di Martino. SASIB International Trialists, Cape Town, South Africa P Douglas, A Hacking, H Høst, A Lindtner, G Notter. Saskatchewan Cancer Foundation, Regina, Canada A J S Bryant, G H Ewing, L A Firth, J L Krushen-Kosloski. Scandinavian Adjuvant Chemotherapy Study Group, Oslo, Norway R Nissen-Meyer. South Sweden Breast Cancer Group, Lund, Sweden H Anderson, F Killander, P Malmström, L Rydén. South-East Sweden Breast Cancer Group, Linköping, Sweden L-G Arnesson, J Carstensen, M Dufmats, H Fohlin, B Nordenskjöld, M Söderberg. South-Eastern Cancer Study Group and Alabama Breast Cancer Project, Birmingham, AL, USA J T Carpenter. Southampton Oncology Centre, UK N Murray, G T Royle, P D Simmonds. Southwest Oncology Group, San Antonio, TX, USA K Albain, W Barlow, J Crowley, D Hayes, J Gralow, S Green, G Hortobagyi, R Livingston, S Martino, C K Osborne, P M Ravdin. Stockholm Breast Cancer Study Group, Sweden J Adolfsson, J Bergh, T Bondesson, F Celebioglu, K Dahlberg, T Fornander, I Fredriksson, J Frisell, E Göransson, M Iiristo, U Johansson, E Lenner, L Löfgren, P Nikolaidis, L Perbeck, S Rotstein, K Sandelin, L Skoog, G Svane, E af Trampe, C Wadström. Swiss Group for Clinical Cancer Research (SAKK), Bern, and OSAKO, St Gallen, Switzerland M Castiglione, A Goldhirsch, R Maibach, H J Senn, B Thürlimann. Tampere University Hospital, Finland M Hakama, K Holli, J Isola, K Rouhento, R Saaristo. Tel Aviv University, Israel H Brenner, A Hercbergs. The High-Dose Chemotherapy for Breast Cancer Study Group (PEGASE), France A L Martin, H Roché. Tokyo Cancer Institute Hospital, Japan M Yoshimoto. Toronto-Edmonton Breast Cancer Study Group, Canada A H G Paterson, K I Pritchard. Toronto Princess Margaret Hospital, Canada A Fyles, J W Meakin, T Panzarella, K I Pritchard. Tunis Institut Salah Azaiz, Tunisia J Bahi. UK Multicentre Cancer Chemotherapy Study Group, London, UK M Reid, M Spittle. UK/ANZ DCIS Trial H Bishop, N J Bundred, J Cuzick, I O Ellis, I S Fentiman, J F Forbes, S Forsyth, W D George, S E Pinder, I Sestak. UK/Asia Collaborative Breast Cancer Group, London, UK G P Deutsch, R Gray, D L W Kwong, V R Pai, R Peto, F Senanayake. University and Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy on behalf of GROCTA trialists F Boccardo, A Rubagotti. University College London, UK M Baum, S Forsyth, A Hackshaw, J Houghton, J Ledermann, K Monson, JS Tobias. University Federico II, Naples, Italy C Carlomagno, M De Laurentiis, S De Placido. University of Edinburgh, UK L Williams. University of Michigan, USA D Hayes, L J Pierce. University of Texas MD Anderson Cancer Center, Houston, TX, USA K Broglio, A U Buzdar. University of Wisconsin, USA R R Love. Uppsala-Örebro Breast Cancer Study Group, Sweden J Ahlgren, H Garmo, L Holmberg, G Liljegren, H Lindman, F Wärnberg. US Oncology, Houston, USA L Asmar, S E Jones. West German Study Group (WSG), Germany O Gluz, N Harbeck, C Liedtke, U Nitz. West of Scotland Breast Trial Group, Glasgow, UK A Litton. West Sweden Breast Cancer Study Group, Gothenburg, Sweden A Wallgren, P Karlsson, B K Linderholm. Western Cancer Study Group, Torrance, CA, USA R T Chlebowski. Würzburg University, Germany H Caffier.
allemaal zeggen dat Tamoxifen helemaal toppiejoppie is, geloof ik het wel.
The Lancet, Early Online Publication, 29 July 2011, doi:10.1016/S0140-6736(11)60993-8
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) [abstract] [FT PDF]
Premenopauzale vrouwen vanaf de geringste ER+ in borstkanker (>10—19 fmol/mg cytosol protein) tenminste vijf jaar op de Tamoxifen.
[X] Check!

Crypto:
Niet een beetje èrg kort door de bocht? Gezien alle commotie over Tamoxifen van de afgelopen jaren trek ik dit eigenlijk niet en ben dan ook allesbehalve onder de indruk van/blij met de gekopieerde waslijst Huppeldepup en Huppeldepup x tig.
In 1e instantie schrok ik me te pletter, want ben o.a. ik dan verkeerd behandeld?!
Na twee jaar Tamoxifen kreeg ik het dringende advies om -achteraf gezien- dit middel toch maar niet vijf jaar te slikken, maar dat het verstandiger was om over te stappen op een aromatase-remmer.
Niet dat ik van die hele studie veel kan volgen, maar gelukkig snap ik dit wel:
Nog een insteek om te nuanceren:
http://www.nki.nl/Ziekenhuis/Nieuws/Archief/2010/Informatie+naar+aanleiding+van+uitzending+Labyrint.htm
quote:
Crypto:
Dat kan ik dus nog steeds niet zeggen.
Volgens de onderzoekers niet
Bovenstaand is mbt hernieuwd optreden van BC. Bij patiënten die geen ER+ status hadden, had Tamoxifen geen effect. Mbt 1 à 2 vs. 5 jaar:
Maar ik kan natuurlijk in geen velden of wegen een oordeel vellen over de keuze van je arts.
Uit het hoofd:
Het is regel na twee jaar aromatase-remmers te geven ná Tamofixen én in postmenopauzale vrouwen met hormoongevoelige borstkanker én Her 2 overexpressie. Dat werkt (voor die groep) nóg beter dan Tamofixen alleen voor vijf jaar.
Bij premenopauzale vrouwen 5 jaar Tamofixen. Alles evt. i.c.m of soms voorafgaande aan operatie etc etc.
Artikel (conclusie) aangepast na opmerkingen van ervaringsdeskundige.
Het mag toch wel gezegd worden dat er met dit middel spectaculaire resultaten worden behaald. Vooral de eerste tien jaar is het positieve effect aanzienlijk. Tientallen procenten! Daarna niveleert zich dat enigszins.
Ze schatten dat ze met 5 jaar therapie op 15 jaar 30% pure winst boeken (en het middel kost daarbij een drol!)
Daar kun je mee thuiskomen zeker als je de grote aantallen vrouwen beschouwd, die voor deze therapie in aanmerking komen. Daarbij is het geen verhaaltje van eventueel, mits en er moet meer onderzoek gebeuren….. Keiharde studie, keiharde aanbevelingen (hoewel er voor de vlooiers altijd wel wat te vinden is).
Voer voor beleidsmakers.
Crypto:
Dan zeg ik nu meteen uit m’n blote bulles dat Her2-neu overexpressie alles te maken heeft met het wel of niet inzetten van Herceptin. Nog een middel dat de overlevingskansen van sommige borstkankerpatiënten sterk kan verbeteren.
Bij de weg: het is Tamoxifen en niet Tamofixen.
Dankjewel.
http://medischcontact.artsennet.nl/Nieuwsartikel/100369/Goede-langetermijneffecten-tamoxifen.htm
Goede langetermijneffecten tamoxifen
Tamoxifen heeft op de lange termijn een groot effect op de recidief- en sterftekans bij oestrogeen-receptorpositieve borstkanker. Dat blijkt uit een meta-analyse van verschillende onderzoeken naar het effect van tamoxifen. De Early Breast Cancer Trialists’ Collaborative Group rapporteert hierover in The Lancet.
De onderzoekers verzamelden de individuele patiëntgegevens uit twintig trials waarin ongeveer 5 jaar tamoxifengebruik werd vergeleken met geen tamoxifen als adjuvante behandeling bij vroege borstkanker. Bij oestrogeen-receptornegatieve (ER-negatieve) ziekte had het middel….
Is de eerste groep auteurs allemaal dood?
En ik dacht dat ze tegenwoordig veel strengere criteria hadden over auteurschap… Of hebben deze mensen allemaal meegeschreven aan het protocol, data verzameld, data geanalyseerd en het artikel geschreven/gecorrigeerd? (Zal wel even geduurd hebben voor al het commentaar verwerkt was, gok ik zo…)
Maar verder: toppiejoppie stuk!